Clinical Trials Logo

Cervical Cancer clinical trials

View clinical trials related to Cervical Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05584332 Terminated - Cervical Cancer Clinical Trials

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: December 9, 2022
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .

NCT ID: NCT05107739 Terminated - Cervical Cancer Clinical Trials

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.

NCT ID: NCT05012397 Terminated - Gastric Cancer Clinical Trials

Milademetan in Advanced/Metastatic Solid Tumors

Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.

NCT ID: NCT04864782 Terminated - Cervical Cancer Clinical Trials

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Start date: September 23, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604) plus chemotherapy in patients with Stage IV, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin.

NCT ID: NCT04762225 Terminated - Melanoma Clinical Trials

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Start date: May 10, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.

NCT ID: NCT04672980 Terminated - Clinical trials for Head and Neck Cancer

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Start date: April 8, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16+ cancers.

NCT ID: NCT04301011 Terminated - Cervical Cancer Clinical Trials

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

RAPTOR
Start date: June 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).

NCT ID: NCT04254107 Terminated - Ovarian Cancer Clinical Trials

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Start date: May 29, 2020
Phase: Phase 1
Study type: Interventional

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).

NCT ID: NCT04230954 Terminated - Cervical Cancer Clinical Trials

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

Drug: Cabozantinib Drug: Pembrolizumab

NCT ID: NCT04187872 Terminated - Clinical trials for Hepatocellular Carcinoma

LITT and Pembrolizumab in Recurrent Brain Metastasis

TORCH
Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).